Patents Represented by Attorney Charles Ryan

Find this attorney in the Justia Lawyer Directory

  • Phthalazine derivatives as inhibitors of protein kinase
    Patent number: 8044041
    Abstract: The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives of formula (III) that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: October 25, 2011
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Gian-Luca Araldi, Matthew Ronsheim, Melanie Ronsheim
  • Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
    Patent number: 8039463
    Abstract: The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: October 18, 2011
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Kumar Sundaresan, Sandeep N. Raikar, Srinivasa Raju Sammeta, Ganesh Prabhu, Hosahalli Subramanya, Alexander Bischoff
  • Pyridoazepine derivatives
    Patent number: 7897595
    Abstract: The present invention relates to pyridoazepine derivatives that act as 5-HT ligands, e.g., 5-HT2 C. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: March 1, 2011
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Gian-Luca Araldi, Alexander Bischoff, Nhut K. Diep
  • Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
    Patent number: 7842696
    Abstract: The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: November 30, 2010
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Alexander Bischoff, Hosahalli Subramanya, Kumar Sundaresan, Srinivasa Raju Sammeta, Anil Kumar Vaka
  • Compositions comprising nebivolol
    Patent number: 7838552
    Abstract: Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: November 23, 2010
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Eric Davis, John P. O'Donnell, Peter Bruce Bottini, Andrew Shaw, R. Preston Mason
  • Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
    Patent number: 7829569
    Abstract: The present invention relates to novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives and, more particularly, to novel solvate and crystalline forms of trans-1{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride. Processes for the preparation of these forms, compositions containing these forms, and methods of use thereof are also described.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: November 9, 2010
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Xiangmin Liao, Haijian Zhu, Andreas Grill
  • Compositions comprising nebivolol
    Patent number: 7803838
    Abstract: Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: September 28, 2010
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Eric Davis, John O'Donnell, Peter Bottini